Zobrazeno 31 - 40
of 55
pro vyhledávání: '"Dirk Huebner"'
Autor:
Dirk Huebner, Alexander R. Macalalad, Hongbo Yang, Andy Chi, Oluwatoyin Shonukan, R. Lutes, Vijayveer Bonthapally, Eric Q. Wu
Publikováno v:
Value in Health. 16(7)
Autor:
Kimberly Perez, Kian Behbakht, Feng Gao, Jacob Zhang, Brittany Bahamon, Angela DeMichele, Ursula A. Matulonis, Antoine Adenis, Huifeng Niu, Elizabeth Claire Dees, Robert L. Coleman, Bohuslav Melichar, Hadi Danaee, Dirk Huebner, Russell J. Schilder, Hyunjin Shin, Jeffrey Ecsedy
Publikováno v:
Journal of Clinical Oncology. 34:2583-2583
2583Background: Alisertib (MLN8237) is an investigational, oral, selective Aurora A kinase inhibitor. The Aurora A gene contains two functional SNPs (codon 31 and codon 57) that modify kinase activ...
Autor:
Jeremy Teasell, Vijayveer Bonthapally, Ashish Gautam, Akshara Richhariya, Esprit Ma, Shih-Yuan Lee, Yanyan Zhu, Dirk Huebner, Erin Zagadailov
Publikováno v:
Journal of Clinical Oncology. 34:20-20
20 Background: AETHERA (NCT01100502) is a randomized Phase 3 study of BV and best supportive care (BSC) vs placebo (PBO) and BSC in the treatment of pts at risk of residual HL post-ASCT. BV consolidation therapy post-ASCT significantly improved progr
Autor:
Muneer H. Abidi, Andy I. Chen, Tamas Masszi, Auayporn Nadamanee, Veronika Bachanova, Naomi N. H. Hunder, Patrick J. Stiff, Simonetta Viviani, Anna Sureda, Angelo Michele Carella, Dirk Huebner, Jan Walewski, Emily K. Larsen, Jerzy Holowiecki, Craig H. Moskowitz, Dzhelil Osmanov, John W. Sweetenham, Edward Agura
Publikováno v:
Blood. 126:3172-3172
Introduction The AETHERA trial is a phase 3, randomized, placebo-controlled trial (ClinicalTrials.gov #NCT01100502), which evaluated whether post-ASCT consolidation treatment with brentuximab vedotin (BV) could prevent disease progression in Hodgkin
Autor:
Joseph D. Rosenblatt, Ajay K. Gopal, Stephen M. Ansell, Robert T. Chen, Dirk Huebner, Emily K. Larsen, Joseph M. Connors, Anas Younes, Scott E. Smith, Andreas Engert, Kerry J. Savage, Abraham P. Fong
Publikováno v:
Blood. 126:2736-2736
Background: Classical Hodgkin lymphoma (HL) is characterized by the presence of CD30-positive Hodgkin Reed-Sternberg cells. The standard of care for patients (pts) with relapsed or refractory (R/R) HL is salvage chemotherapy followed by high dose che
Autor:
Andres Forero-Torres, Michelle A. Fanale, Steven M. Horwitz, Ranjana H. Advani, Nancy L. Bartlett, Andrew Davies, Barbara Pro, Andrei R. Shustov, Robert T. Chen, Dana A. Kennedy, Timothy M Illidge, Dirk Huebner
Publikováno v:
Blood. 126:1537-1537
Background: Peripheral T-cell lymphomas (PTCL) encompass a subset of aggressive non-Hodgkin lymphomas. Many PTCL tumor cells express the surface marker CD30, including systemic anaplastic large cell lymphoma (ALCL) where CD30 is uniformly expressed.
Autor:
Jerzy Holowiecki, Dzhelil Osmanov, Craig H. Moskowitz, John W. Sweetenham, Angelo Michele Carella, Alessandro Gianni, Patrick J. Stiff, Andy I. Chen, Jan Walewski, Yin Yang, Tamas Masszi, Dirk Huebner, Edward Agura, Auayporn Nadamanee, Naomi N. H. Hunder, Anna Sureda, Muneer H. Abidi
Publikováno v:
Biology of Blood and Marrow Transplantation. 20(2):S115-S116
Autor:
Emily K. Larsen, Naomi N. H. Hunder, Jerzy Holowiecki, Simonetta Viviani, Auayporn Nademanee, Jan Walewski, John W. Sweetenham, Shih-Yuan Lee, Tamas Masszi, Veronika Bachanova, Muneer H. Abidi, Patrick J. Stiff, Craig H. Moskowitz, Andy I. Chen, Dirk Huebner
Publikováno v:
Journal of Clinical Oncology. 33:8519-8519
8519 Background: In the phase III, randomized, placebo-controlled AETHERA trial, PFS was significantly improved with brentuximab vedotin (BV) vs placebo (HR=0·57, P=0·001) in HL pts at risk of prog...
Autor:
Dirk Huebner, Craig H. Moskowitz, Patrick J. Stiff, Jerzy Holowiecki, Andy I. Chen, Dzhelil Osmanov, Auayporn Nadamanee, Veronika Bachanova, Tamas Masszi, Emily K. Larsen, Muneer H. Abidi, John W. Sweetenham, Naomi N. H. Hunder, Anna Sureda, Jan Walewski, Alessandro M. Gianni, Angelo Michele Carella, Edward Agura
Publikováno v:
Blood. 124:673-673
Background For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), providing a cure for approximately 50% of
Autor:
Owen A. O'Connor, Dirk Huebner, Emily K. Larsen, Timothy M Illidge, Lorenz Trümper, Barbara Pro, Dana A. Kennedy
Publikováno v:
Annals of Oncology. 25:iv338
Background: MTCL including systemic anaplastic large cell lymphoma (sALCL) are aggressive neoplasms. Anthracycline-based multiagent chemotherapy regimens have demonstrated response rates ranging from 76 to 88%. Five-year overall survival rates range